Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

Colorectal Cancer is an esteemed academic journal published by Taylor & Francis Ltd, focusing on all aspects of colorectal cancer research, diagnosis, treatment, and prevention. With an ISSN of 1758-194X and an E-ISSN of 1758-1958, this journal serves as a critical platform for publishing innovative studies, clinical trials, and meta-analyses to advance the understanding of colorectal cancer. Though not yet categorized under open access, it provides valuable insights and is committed to enhancing the visibility of research contributions within the field. The journal aims to foster collaboration and communication among researchers, clinicians, and students dedicated to improving patient outcomes and exploring novel therapeutic strategies. With its rigorous editorial standards, Colorectal Cancer plays a pivotal role in shaping future research and clinical practices, making it indispensable for professionals in oncology, gastroenterology, and related fields.

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, published by BMJ PUBLISHING GROUP, is a leading interdisciplinary journal focused on advancing research and clinical practice in the field of gynecological oncology. With an ISSN of 1048-891X and an E-ISSN of 1525-1438, the journal has established itself as a vital resource since its inception in 1991, covering cutting-edge advancements through 2024 and beyond. The journal holds esteemed rankings, including Q1 in Obstetrics and Gynecology and Q2 in Oncology, highlighting its influence and high citation impact within the medical community. Its Scopus rankings underscore its prominence, placing it among the top 13% of journals in Obstetrics and Gynecology and the top 27% in Oncology. Although it does not currently offer Open Access options, the journal provides a platform for researchers, clinicians, and students to share significant findings and developments that shape the future of gynecological cancer research and treatment. The INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER stands as a significant pillar in the ongoing effort to improve patient outcomes and foster innovation in this critical area of healthcare.